Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryApr 17, 2017	Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors MONROVIA, Calif. , April 17, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Kevin Gorman , Ph.D., chief executive officer of Neurocrine	View HTML Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors 18 KB
Toggle SummaryMar 15, 2017	Xencor to Present at Oppenheimer 27th Annual Healthcare Conference MONROVIA, Calif. , March 15, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at Oppenheimer 27th Annual Healthcare Conference 13.8 KB
Toggle SummaryMar 06, 2017	Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders MONROVIA, Calif. , March 6, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Bruce L.A. Carter , Ph.D., will not stand for reelection to the	View HTML Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders 16.7 KB
Toggle SummaryMar 01, 2017	Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting Abstracts available on the AACR Annual Meeting website	View HTML Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting 77.5 KB
Toggle SummaryFeb 28, 2017	Xencor Reports Fourth Quarter and Full Year 2016 Financial Results -- Reported promising preliminary data from Phase 2 study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) ----Announced strategic collaboration with Novartis for bispecific antibodies---- Robust cash position supports operations beyond 2020 ---- Management to host conference call today at 4:30 p.m. ET --	View HTML Xencor Reports Fourth Quarter and Full Year 2016 Financial Results 110.5 KB
Toggle SummaryFeb 22, 2017	Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017 MONROVIA, Calif. , Feb. 22, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and	View HTML Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017 14.4 KB
Toggle SummaryFeb 18, 2017	IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis MONROVIA, Calif. , Feb. 18, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that investigators John H.	View HTML IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis 73.1 KB
Toggle SummaryFeb 09, 2017	Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference MONROVIA, Calif. , Feb. 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference 14 KB
Toggle SummaryDec 06, 2016	Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock MONROVIA, Calif. , Dec. 6, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced the completion of an underwritten public offering of 5,272,750 shares of its common stock, including 687,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to	View HTML Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock 381.5 KB
Toggle SummaryDec 01, 2016	Xencor, Inc. Prices Public Offering of Common Stock MONROVIA, Calif. , Dec. 1, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced the pricing of an underwritten public offering of 4,585,000 shares of its common stock, offered at a price to the public of $24.00 per share. The gross proceeds from this offering to Xencor are expected	View HTML Xencor, Inc. Prices Public Offering of Common Stock 393.7 KB

Tools

Press Releases